CPC
ARQT icon

Cookson Peirce & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

Cookson Peirce & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$189K – 321
2025
Q3 		$189K Buy
+10,000
New +$158K 0.01% 301
2025
Q2 		– Sell
-57,613
Closed -$901K – 276
2025
Q1 		$901K Buy
+57,613
New +$812K 0.05% 147

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cookson Peirce & Co's ARQT Position: Q4 2025 in Review

Cookson Peirce & Co sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 10,000 shares — an estimated $189K sold.

Cookson Peirce & Co first reported a position in ARQT in Q1 2025 and held it in 2 quarters. The position peaked at $901K in Q1 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Cookson Peirce & Co reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Cookson Peirce & Co sold 10,000 Arcutis Biotherapeutics shares in Q4 2025, an estimated $189K.
  • Cookson Peirce & Co first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 2 quarters.
  • Cookson Peirce & Co's Arcutis Biotherapeutics position peaked at $901K in Q1 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Cookson Peirce & Co's 13F filing for Q4 2025, filed 11 Feb 2026.